MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

Search

AbbVie Inc

Geschlossen

BrancheGesundheitswesen

201.54 -1.65

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

201.41

Max

210.37

Schlüsselkennzahlen

By Trading Economics

Einkommen

-1.6B

-23M

Verkäufe

642M

15B

KGV

Branchendurchschnitt

87.665

63.778

EPS

2.16

Dividendenrendite

3.13

Gewinnspanne

-0.152

Angestellte

55,000

EBITDA

-4.4B

535M

Empfehlungen

By TipRanks

Empfehlungen

Starkes Kaufsignal

12-Monats-Prognose

+5.06% upside

Dividenden

By Dow Jones

Dividendenrendite

Branchendurchschnitt

3.13%

2.39%

Nächstes Ergebnis

25. Apr. 2025

Nächste Dividendenausschüttung

15. Mai 2025

Nächstes Ex-Dividendendatum

15. Apr. 2025

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

36B

371B

Vorheriger Eröffnungskurs

203.19

Vorheriger Schlusskurs

201.54

Nachrichtenstimmung

By Acuity

29%

71%

72 / 386 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Neutral Evidence

AbbVie Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

27. Feb. 2025, 22:48 UTC

Akquisitionen, Fusionen, Übernahmen

Mustang Bio to Exit Lease of Worcester, Mass. Manufacturing Facility

12. Feb. 2025, 13:41 UTC

Wichtige Markttreiber

Xilio Therapeutics Shares Surge Premarket on AbbVie Deal

31. Jan. 2025, 13:28 UTC

Ergebnisse

AbbVie 4Q Revenue Tops Estimates as Skyrizi, Rinvoq Growth Surges

14. März 2025, 09:30 UTC

Top News

Big Pharma Walked Away From Mental Health. Why Some Are Coming Back. -- Heard on the Street -- WSJ

3. März 2025, 15:04 UTC

Akquisitionen, Fusionen, Übernahmen

AbbVie Enters The Obesity Arena. Why It's Paying Up To $2.23 Billion. -- IBD

28. Feb. 2025, 12:00 UTC

Top News

Drug Stocks Are the New Safe Bet in a Shaky Market -- Heard on the Street -- WSJ

6. Feb. 2025, 13:25 UTC

Top News
Ergebnisse

Bristol Myers Earnings Are a 'Tale of 2 Trends' as Guidance Falls Short. The Stock Is Falling -- Barrons.com

6. Feb. 2025, 12:00 UTC

Ergebnisse

Bristol Myers Earnings Are 'a Tale of 2 Trends' as Guidance Falls Short -- Barrons.com

5. Feb. 2025, 12:00 UTC

Top News

Merck Is Suffering From a Classic Pharma Problem -- Heard on the Street -- WSJ

31. Jan. 2025, 15:50 UTC

Top News
Ergebnisse

AbbVie Stock Jumps on Earnings and Revenue Beat -- Barrons.com

31. Jan. 2025, 13:51 UTC

Ergebnisse

AbbVie Jumps After Its Powerhouses, Skyrizi And Rinvoq, Continued To Dominate -- IBD

31. Jan. 2025, 13:47 UTC

Top News
Ergebnisse

AbbVie Stock Jumps on Earnings and Revenue Beat -- Barrons.com

31. Jan. 2025, 13:24 UTC

Market Talk
Ergebnisse

AbbVie Gets More Upbeat on Skyrizi, Rinvoq -- Market Talk

31. Jan. 2025, 12:46 UTC

Ergebnisse

AbbVie's Stock Pops 4% After Earnings Beat Estimates And Company Offers Upbeat View Of 2025 -- MarketWatch

31. Jan. 2025, 12:39 UTC

Ergebnisse

AbbVie 4Q Global Rinvoq Net Revenue $1.83B, Up 46.2% >ABBV

31. Jan. 2025, 12:38 UTC

Ergebnisse

AbbVie: Expect 2025 Revenue to Exceed Previous Peak >ABBV

31. Jan. 2025, 12:38 UTC

Ergebnisse

AbbVie Now Sees Aesthetics Delivering High-Single-Digit Compound Annual Revenue Growth From 2025-2029 >ABBV

31. Jan. 2025, 12:37 UTC

Ergebnisse

AbbVie Raises 2027 Combined Sales Outlook for Skyrizi, Rinvoq to More Than $31B >ABBV

31. Jan. 2025, 12:37 UTC

Ergebnisse

AbbVie Reaffirms Expectations for High-Single-Digit Compound Annual Revenue Growth Rate Through 2029 >ABBV

31. Jan. 2025, 12:36 UTC

Ergebnisse

AbbVie: 4Q Revenue Rose 6.1% on Operational Basis >ABBV

31. Jan. 2025, 12:36 UTC

Ergebnisse

AbbVie 4Q Loss $22M >ABBV

31. Jan. 2025, 12:36 UTC

Ergebnisse

AbbVie 4Q U.S. HUMIRA Rev $1.25B >ABBV

31. Jan. 2025, 12:36 UTC

Ergebnisse

AbbVie 4Q Global Net Rev From Oncology Portfolio $1.69B >ABBV

31. Jan. 2025, 12:36 UTC

Ergebnisse

AbbVie 4Q Global Skyrizi Rev $3.78B >ABBV

31. Jan. 2025, 12:36 UTC

Ergebnisse

AbbVie 4Q International HUMIRA Rev $436M >ABBV

31. Jan. 2025, 12:36 UTC

Ergebnisse

AbbVie 4Q Adj EPS $2.16 >ABBV

31. Jan. 2025, 12:36 UTC

Ergebnisse

AbbVie Sees FY Adj EPS $12.12-Adj EPS $12.32 >ABBV

31. Jan. 2025, 12:36 UTC

Ergebnisse

AbbVie 4Q Loss/Shr 2c >ABBV

31. Jan. 2025, 12:36 UTC

Ergebnisse

AbbVie 4Q Global IMBRUVICA Rev $848M >ABBV

31. Jan. 2025, 12:36 UTC

Ergebnisse

AbbVie 4Q Rev $15.1B >ABBV

Peer-Vergleich

Kursveränderung

AbbVie Inc Prognose

Kursziel

By TipRanks

5.06% Vorteil

12-Monats-Prognose

Durchschnitt 215.57 USD  5.06%

Hoch 240 USD

Tief 190 USD

Basierend auf 16 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für AbbVie Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

16 ratings

12

Buy

4

Halten

0

Sell

Technischer Score

By Trading Central

201.34 / 210.78Unterstützung & Widerstand

Kurzfristig

Neutral Evidence

Mittelfristig

Bullish Evidence

Langfristig

Weak Bullish Evidence

Stimmung

By Acuity

72 / 386 Ranking in Gesundheitswesen

Nachrichtenstimmung

Bullische Evidenz

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Unterdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über AbbVie Inc

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; Evolveimmune Therapeutics, Inc.; Genentech, Inc.; AbCellera Biologics Inc.; and Tentarix Biotherapeutics, LP. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.